The claim by DrMalpani.com that PRP treatments in fertility care are scams is supported by critical analysis of available evidence, despite some studies reporting positive outcomes. Here’s a breakdown of the key points:
1. Limited High-Quality Evidence for PRP Efficacy
While some studies report benefits, they often lack rigor:
Small sample sizes: Many studies (e.g., 83 women in Melo et al. 1, 51 patients in the Romanian trial 4) are underpowered to draw definitive conclusions.
Lack of randomization: The 2023 intraovarian PRP study (469 women) was observational and non-randomized, increasing bias risk2.
Inconsistent results: Live birth rates in PRP groups (8.7% vs. 2.7% controls) failed statistical significance in one trial1, undermining clinical relevance.
2. Risks and Unproven Mechanisms
Potential harm: Intraovarian PRP injections may damage ovarian tissue or cause infections12, yet no long-term safety data exist.
Theoretical basis questioned: PRP’s growth factors (e.g., VEGF, TGF-β) are hypothesized to aid regeneration, but their direct impact on ovarian or endometrial function remains unvalidated34.
3. Exploitation of Vulnerable Patients
Targeting hopeless cases: PRP is often marketed to women with premature ovarian failure or thin endometrium—groups desperate for solutions24.
High costs, low success: Clinics charge premium fees for PRP (e.g., $3,000–$5,000 per cycle) despite uncertain outcomes5.
4. Scientific Consensus Calls for Caution
Systematic reviews: A 2021 narrative review noted “promising results” but emphasized “limited evidence” and the need for RCTs1.
Ethical concerns: Researchers warn against clinical use until larger trials confirm efficacy23. For example, the 2023 intraovarian PRP study concluded: “Future randomised clinical trials are needed… before offering it routinely”2.
Contradictory Evidence
Some studies report benefits but with caveats:
Conclusion
DrMalpani.com’s skepticism aligns with the broader scientific community’s stance: while PRP shows potential, its current use in fertility clinics often lacks robust evidence, exploits vulnerable patients, and risks harm. Until large-scale RCTs validate its efficacy and safety, labeling it a “scam” reflects concerns over unethical commercialization of unproven therapies5.
Need more guidance?
Please get your doubts resolved free using our chatbot which is powered by AI based on Dr Malpani’s 40 years of clinical expertise and experience at https://www.drmalpani.com/chat-w-chatbot/index.html. This will ensure you’re on the right path and potentially save significant costs in the long run.